Lamin A Inhibitors
Lamin A inhibitors are a class of chemical compounds that target the lamin A protein, a key component of the nuclear lamina, which is a structural meshwork lining the inner membrane of the nuclear envelope in eukaryotic cells. Lamin A is a type of intermediate filament protein that plays a vital role in maintaining nuclear structure, regulating gene expression, and participating in DNA repair and chromatin organization. Inhibitors of lamin A disrupt its ability to form a stable nuclear lamina, which can lead to changes in nuclear morphology, altered mechanical properties of the nucleus, and impacts on cellular processes that depend on the integrity of the nuclear envelope.
The mechanisms by which lamin A inhibitors act can vary depending on their specific targets. Some inhibitors may interfere with the post-translational processing of prelamin A, preventing its proper maturation into functional lamin A, while others may directly bind to lamin A, disrupting its ability to polymerize into the nuclear lamin A. By blocking lamin A function, these compounds can affect several important cellular pathways, such as those involved in mechanotransduction, the transmission of mechanical signals from the cellular environment to the nucleus. Additionally, lamin A inhibitors provide valuable insights into the role of the nuclear lamina in regulating nuclear stiffness, gene regulation, and cell differentiation. Through the inhibition of lamin A, researchers can study how disruptions in nuclear structure influence cellular behavior and the broader implications of nuclear envelope integrity in cell biology.
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Simvastatin | 79902-63-9 | sc-200829 sc-200829A sc-200829B sc-200829C | 50 mg 250 mg 1 g 5 g | $30.00 $87.00 $132.00 $434.00 | 13 | |
Simvastatin, a cholesterol-lowering statin, indirectly influences Lamin A through the mevalonate pathway. By inhibiting HMG-CoA reductase, Simvastatin reduces farnesylation, a crucial post-translational modification for Lamin A. This interference disrupts Lamin A's anchorage to the nuclear envelope, impacting nuclear structure and potentially affecting cellular processes regulated by Lamin A. | ||||||
Geranylgeraniol | 24034-73-9 | sc-200858 sc-200858A | 20 mg 100 mg | $159.00 $465.00 | 14 | |
Geranylgeraniol (GGO), a downstream product of the mevalonate pathway, influences Lamin A indirectly by serving as a precursor for geranylgeranylation. By providing the geranylgeranyl lipid moiety, GGO supports proper post-translational modification of Lamin A, essential for its correct localization to the nuclear envelope. Exploring the impact of GGO on Lamin A offers insights into the regulation of nuclear structure and cellular processes dependent on Lamin A integrity. | ||||||
Mevastatin (Compactin) | 73573-88-3 | sc-200853 sc-200853A | 10 mg 50 mg | $75.00 $175.00 | 18 | |
Mevastatin, like Simvastatin, is a statin that indirectly affects Lamin A through the mevalonate pathway. By inhibiting HMG-CoA reductase, Mevastatin disrupts the synthesis of isoprenoid intermediates, leading to altered post-translational modifications of Lamin A. This interference can influence the proper localization of Lamin A to the nuclear envelope, impacting nuclear structure and potentially modulating cellular processes regulated by Lamin A. | ||||||
N-Acetyl-S-farnesyl-L-cysteine (AFC) | 135304-07-3 | sc-200839 sc-200839A | 5 mg 25 mg | $86.00 $225.00 | ||
N-Acetyl-S-farnesyl-L-cysteine (AFC) is a farnesylcysteine analog, acting as a competitive inhibitor of farnesyltransferase. By competing for farnesyltransferase binding, AFC disrupts the farnesylation of proteins, including Lamin A. This interference influences Lamin A's proper localization to the nuclear envelope, potentially impacting nuclear structure and cellular processes dependent on intact nuclear architecture. | ||||||
Pravastatin, Sodium Salt | 81131-70-6 | sc-203218 sc-203218A sc-203218B | 25 mg 100 mg 1 g | $68.00 $159.00 $772.00 | 2 | |
Pravastatin, a statin, indirectly influences Lamin A through the mevalonate pathway. By inhibiting HMG-CoA reductase, Pravastatin disrupts the synthesis of isoprenoid intermediates, leading to altered post-translational modifications of Lamin A. This interference can impact the proper localization of Lamin A to the nuclear envelope, influencing nuclear structure and potentially modulating cellular processes regulated by Lamin A. | ||||||
JNK Inhibitor XVI | 1410880-22-6 | sc-364745 | 10 mg | $350.00 | 5 | |
JNK-IN-8 is a selective JNK (c-Jun N-terminal kinase) inhibitor. JNK is implicated in cellular processes, and its inhibition by JNK-IN-8 may indirectly affect Lamin A through downstream signaling pathways. Although the specific interactions are not fully elucidated, JNK-IN-8 provides a tool to explore the intricate crosstalk between JNK signaling and Lamin A, potentially influencing nuclear structure and cellular functions. | ||||||
GGTI 298 | 1217457-86-7 | sc-361184 sc-361184A | 1 mg 5 mg | $189.00 $822.00 | 2 | |
GGTI-298 is a geranylgeranyltransferase I inhibitor, impacting the geranylgeranylation of proteins, including Lamin A. Through the inhibition of Lamin A geranylgeranylation, GGTI-298 disrupts its association with the nuclear envelope, potentially influencing nuclear structure and function. The compound offers a targeted means to investigate the effects of Lamin A geranylgeranylation on cellular processes and diseases associated with nuclear envelope integrity. | ||||||